BioScrip (BIOS) Trading Up 7.5%
BioScrip Inc (NASDAQ:BIOS) shares were up 7.5% on Tuesday . The stock traded as high as $3.79 and last traded at $3.74. Approximately 1,041,775 shares changed hands during trading, an increase of 45% from the average daily volume of 716,155 shares. The stock had previously closed at $3.48.
Several research analysts recently weighed in on BIOS shares. Lake Street Capital lifted their price target on BioScrip from $4.50 to $10.00 and gave the company a “buy” rating in a research report on Friday, December 7th. Canaccord Genuity started coverage on BioScrip in a research report on Wednesday, December 12th. They set a “buy” rating and a $5.00 price target for the company. BidaskClub upgraded BioScrip from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 21st. Barrington Research reiterated a “buy” rating and set a $4.00 price target on shares of BioScrip in a research report on Friday, October 5th. Finally, TheStreet upgraded BioScrip from a “d+” rating to a “c-” rating in a research report on Monday, November 26th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $4.88.
The stock has a market cap of $437.90 million, a PE ratio of -9.21 and a beta of 0.61.
A number of institutional investors have recently bought and sold shares of BIOS. Metropolitan Life Insurance Co. NY lifted its position in BioScrip by 77.3% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 45,013 shares of the company’s stock worth $132,000 after acquiring an additional 19,625 shares during the period. Engineers Gate Manager LP acquired a new stake in BioScrip during the 3rd quarter worth approximately $146,000. MetLife Investment Advisors LLC lifted its position in BioScrip by 220.8% during the 2nd quarter. MetLife Investment Advisors LLC now owns 64,727 shares of the company’s stock worth $190,000 after acquiring an additional 44,548 shares during the period. Citadel Advisors LLC lifted its position in BioScrip by 471.9% during the 3rd quarter. Citadel Advisors LLC now owns 66,502 shares of the company’s stock worth $206,000 after acquiring an additional 54,874 shares during the period. Finally, B. Riley Wealth Management Inc. acquired a new stake in BioScrip during the 3rd quarter worth approximately $326,000. 82.09% of the stock is owned by institutional investors.
About BioScrip (NASDAQ:BIOS)
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
Recommended Story: Preferred Stock
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.